significantnew treatment
Avapritinib approved by EMA for advanced SM based on PATHFINDER trial
Systemic Mastocytosis →Summary
The EMA granted marketing authorization for avapritinib in advanced SM in June 2022, based on the PATHFINDER trial showing an overall response rate of 75% and complete remission in 36% of patients. Avapritinib demonstrated superiority over midostaurin with deeper molecular responses and better tolerability.
More from Systemic Mastocytosis
significantTreatment update
PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM
significantNew research
Swedish and Danish population-based studies reveal higher SM prevalence than expected
breakthroughTreatment update
Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)
incrementalTreatment update
Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable
ID: systemic-mastocytosis-update-8Type: new_treatmentImpact: significant